PTEN loss drives B7H3 upregulation via the mTORC2/FOXO/c-Myc axis to promote tumor immune escape in ovarian cancer
Authors:
Open Access
- 31 March 2026
- journal article
- Published by Elsevier in Cell Reports
- Vol. 45 (4) , 117198
Abstract
No abstract availableKeywords
Funding Information
- China Postdoctoral Science Foundation (2025M781980)
- National Natural Science Foundation of China (82303336)
- National Natural Science Foundation of China (U25A20117)
- National Natural Science Foundation of China (82072889)
- National Natural Science Foundation of China (82372928)
- National Natural Science Foundation of China (82573510)
This publication has 58 references indexed in Scilit:
- Recent highlights of cancer immunotherapyHolistic Integrative Oncology, 2023
- Dual mTORC1/2 inhibitor AZD2014 diminishes myeloid-derived suppressor cells accumulation in ovarian cancer and delays tumor growthCancer Letters, 2021
- Small-Molecule MYC Inhibitors Suppress Tumor Growth and Enhance ImmunotherapyCancer Cell, 2019
- Efficacy and Safety of Avelumab for Patients With Recurrent or Refractory Ovarian CancerJAMA Oncology, 2019
- mTOR Signaling in Growth, Metabolism, and DiseaseCell, 2017
- Pre-clinical evaluation of AZD-2014, a novel mTORC1/2 dual inhibitor, against renal cell carcinomaCancer Letters, 2015
- Loss of Lkb1 and Pten Leads to Lung Squamous Cell Carcinoma with Elevated PD-L1 ExpressionCancer Cell, 2014
- Genomic Deletion of PTEN Is Associated with Tumor Progression and Early PSA Recurrence in ERG Fusion-Positive and Fusion-Negative Prostate CancerThe American Journal of Pathology, 2012
- MYC on the Path to CancerCell, 2012
- mTOR Complex 2 Is Required for the Development of Prostate Cancer Induced by Pten Loss in MiceCancer Cell, 2009